Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

ATTRibute-CM Top-Line Results Favorable for Acoramidis in Transthyretin Amyloidosis

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

July 17, 2023

COVID-19: TCTMD’s Dispatch for February Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for February Week 4

February 21, 2022

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

News Daily News

Homozygous FH Diagnosis Often Comes Late, With Lackluster Care

Michael O'Riordan

February 10, 2022

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

October 14, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

May 16, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

July 20, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.